Published June 21, 2018
| Version v1
Patent
Open
CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
Creators
- 1. University of Chicago
- 2. Baylor College of Medicine
Contributors
Patent applicants:
Description
Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).
Files
US20180170992.pdf
Files
(6.2 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:7c3e1c73570b36bd01bedecc77583688
|
6.2 MB | Preview Download |
Additional details
Identifiers
- Patent application number
- US 201615545950 A
- Patent number
- US 2018/0170992 A1
- Other
- oai:uchicago.tind.io:8520
Dates
- Patent filed
-
2016-01-26